- Alnylam Pharmaceuticals (NASDAQ:ALNY) Q4 results: Revenues: $37.9M (+116.6%); Operating Loss: ($147.3M) (-27.6%); Net Loss: ($142.2M) (-26.0%); Loss Per Share: ($1.48) (-12.1%); Non-GAAP Loss Per Share: ($1.20) (-11.1%); Quick Assets: $1,704.5M (+80.8%).
- 2018 Guidance: Cash, cash equivalents and investments: ~$1.0B; Non-GAAP R&D expenses: $400M - 440M; Non-GAAP SG&A expenses: $280M - 320M.
Alnylam Pharma reports Q4 results
Recommended For You
More Trending News
About ALNY Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
ALNY | - | - |
Alnylam Pharmaceuticals, Inc. |